- Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer – - Full ...
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results